Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
О роли нейроэндокринных нарушений в патогенезе когнитивной дисфункции при депрессивных состояниях (обзор литературы с комментариями)
О роли нейроэндокринных нарушений в патогенезе когнитивной дисфункции при депрессивных состояниях (обзор литературы с комментариями)
Беккер Р.А., Быков Ю.В. О роли нейроэндокринных нарушений в патогенезе когнитивной дисфункции при депрессивных состояниях (обзор литературы с комментариями). Consilium Medicum. 2016; 18 (4): 57–61. DOI: 10.26442/2075-1753_2016.4.57-61
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Депрессивные состояния часто сопровождаются теми или иными нейроэндокринными нарушениями или бывают коморбидны с эндокринными заболеваниями. В то же время депрессии часто сопровождаются развитием когнитивных нарушений, причем показано, что именно выраженность когнитивных нарушений в наибольшей степени определяет функциональные исходы и возможность социализации больных с депрессиями. В данной статье рассматриваются вопрос о влиянии нейроэндокринных нарушений на параметры когнитивного функционирования депрессивных больных и имеющаяся доказательная база для применения методов гормональной коррекции когнитивных нарушений при депрессивных состояниях, даются общего характера практические рекомендации по применению некоторых из них.
Ключевые слова: депрессивные состояния, когнитивные нарушения, нейроэндокринные нарушения, ось гипоталамус–гипофиз–надпочечники, кортизол, половые гормоны, тиреоидные гормоны, инсулинорезистентность мозга, метаболический синдром.
Key words: major depression, cognitive dysfunction, neuroendocrine dysfunction, HPA axis, cortisol, sex hormones, thyroid hormones, central insulin resistance, metabolic syndrome.
Ключевые слова: депрессивные состояния, когнитивные нарушения, нейроэндокринные нарушения, ось гипоталамус–гипофиз–надпочечники, кортизол, половые гормоны, тиреоидные гормоны, инсулинорезистентность мозга, метаболический синдром.
________________________________________________
Key words: major depression, cognitive dysfunction, neuroendocrine dysfunction, HPA axis, cortisol, sex hormones, thyroid hormones, central insulin resistance, metabolic syndrome.
Полный текст
Список литературы
1. Беккер Р.А., Быков Ю.В. Когнитивные нарушения при депрессиях: клиническое значение и современные возможности терапии. Психиатрия и психофармакотерапия. 2015; 17 (4): 40–5. / Bekker R.A., Bykov Iu.V. Kognitivnye narusheniia pri depressiiakh: klinicheskoe znachenie i sovremennye vozmozhnosti terapii. Psychiatry and Psychopharmacotherapy. 2015; 17 (4): 40–5. [in Russian]
2. Быков Ю.В., Беккер Р.А., Григорьев М.Э. Перспективы применения мелатонина при депрессивных расстройствах (обзор литературы). Consilium Medicum. 2013; 15 (9): 90–5. / Bykov Iu.V., Bekker R.A., Grigor'ev M.E. Perspektivy primeneniia melatonina pri depressivnykh rasstroistvakh (obzor literatury). Consilium Medicum. 2013; 15 (9): 90–5. [in Russian]
3. Быков Ю.В., Беккер Р.А., Резников М.К. Депрессии и резистентность. М.: ИНФРА-М, 2013. / Bykov Iu.V., Bekker R.A., Reznikov M.K. Depressii i rezistentnost'. M.: INFRA-M, 2013. [in Russian]
4. Мазо Г.Э., Незнанов Н.Г. Терапевтически резистентные депрессии. СПб.: Береста, 2012. / Mazo G.E., Neznanov N.G. Terapevticheski rezistentnye depressii. SPb.: Beresta, 2012. [in Russian]
5. Atsak P, Guenzel FM, Kantar-Gok D et al. Glucocorticoids mediate stress–induced impairment of retrieval of stimulus-response memory. Psychoneuroendocrinology 2016; 67: 207–15.
6. Baitharu I, Deep SN, Jain V et al. Corticosterone synthesis inhibitor metyrapone ameliorates chronic hypobaric hypoxia induced memory impairment in rat. Behav Brain Res 2012; 228 (1): 53–65.
7. Berent–Spillson A, Briceno E, Pinsky A et al. Distinct cognitive effects of estrogen and progesterone in menopausal women. Psychoneuroendocrinology 2015; 59: 25–36.
8. Bortolato B, Miskowiak KW, Köhler CA et al. Cognitive remission: a novel objective for the treatment of major depression? BMC Med 2016; 14: 9.
9. Castanho TC, Moreira PS, Portugal-Nunes C et al. The role of sex and sex-related hormones in cognition, mood and well-being in older men and women. Biol Psychol 2014; 103: 158–66.
10. Chen B, Jin X, Guo R et al. Metabolic Syndrome and Cognitive Performance Among Chinese ≥50 Years: A Cross-Sectional Study with 3988 Participants. Metab Syndr Relat Disord 2016; 14 (4): 222–7.
11. Crowley SK, O'Buckley TK, Schiller CE et al. Blunted neuroactive steroid and HPA axis responses to stress are associated with reduced sleep quality and negative affect in pregnancy: a pilot study. Psychopharmacology (Berl) 2016; 233 (7): 1299–310.
12. Donoghue K, Rose A, Coulton S et al. Double–blind, 12 month follow-up, placebo-controlled trial of mifepristone on cognition in alcoholics: the MIFCOG trial protocol. BMC Psychiatry 2016; 16: 40.
13. Golier JA, Caramanica K, Michaelides AC et al. A randomized, double-blind, placebo-controlled, crossover trial of mifepristone in Gulf War veterans with chronic multisymptom illness. Psychoneuroendocrinology 2016; 64: 22–30.
14. Grimm A, Mensah-Nyagan AG, Eckert A. Alzheimer, mitochondria and gender. Neurosci Biobehav Rev 2016. pii: S0149–7634(15)30066–X.
15. Guo M, Mi J, Jiang QM et al. Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus. Clin Exp Pharmacol Physiol 2014; 41 (9): 650–6.
16. Hackett G. An update on the role of testosterone replacement therapy in the management of hypogonadism. Ther Adv Urol 2016; 8 (2): 147–60.
17. Hallschmid M, Benedict C, Schultes B et al. Towards the therapeutic use of intranasal neuropeptide administration in metabolic and cognitive disorders. Regul Pept 2008; 149 (1–3): 79–83.
18. Han L, Cai W, Mao L et al. Rosiglitazone Promotes White Matter Integrity and Long-Term Functional Recovery After Focal Cerebral Ischemia. Stroke 2015; 46 (9): 2628–36.
19. Hara Y, Waters EM, McEwen BS et al. Estrogen Effects on Cognitive and Synaptic Health Over the Lifecourse. Physiol Rev 2015; 95 (3): 785–807.
20. Horie NC, Serrao VT, Simon SS et al. Cognitive Effects of Intentional Weight Loss in Elderly Obese Individuals With Mild Cognitive Impairment. J Clin Endocrinol Metab 2016; 101 (3): 1104–12.
21. Howland RH. Mifepristone as a therapeutic agent in psychiatry. J Psychosoc Nurs Ment Health Serv 2013; 51 (6): 11–4.
22. Lehert P, Villaseca P, Hogervorst E et al. Individually modifiable risk factors to ameliorate cognitive aging: a systematic review and meta–analysis. Climacteric 2015; 18 (5): 678–89.
23. Lenze EJ, Hershey T, Newcomer JW et al. Antiglucocorticoid therapy for older adults with anxiety and co–occurring cognitive dysfunction: results from a pilot study with mifepristone. Int J Geriatr Psychiatry 2014; 29 (9): 962–9.
24. Lupien SJ, Wilkinson CW, Brière S et al. Acute modulation of aged human memory by pharmacological manipulation of glucocorticoids. J Clin Endocrinol Metab 2002; 87 (8): 3798–807.
25. Mahmoud R, Wainwright SR, Galea LA. Sex hormones and adult hippocampal neurogenesis: Regulation, implications, and potential mechanisms. Front Neuroendocrinol 2016. pii: S0091–3022(16)30010–3.
26. McIntyre RS, Soczynska JK, Woldeyohannes HO et al. Thiazolidinediones: novel treatments for cognitive deficits in mood disorders? Expert Opin Pharmacother 2007; 8 (11): 1615–28.
27. Mesripour A, Hajhashemi V, Rabbani M. Metyrapone and mifepristone reverse recognition memory loss induced by spontaneous morphine withdrawal in mice. Basic Clin Pharmacol Toxicol 2008; 102 (4): 377–81.
28. Moon JH. Endocrine Risk Factors for Cognitive Impairment. Endocrinol Metab (Seoul) 2016.
29. Ott V, Benedict C, Schultes B et al. Intranasal administration of insulin to the brain impacts cognitive function and peripheral metabolism. Diabetes Obes Metab 2012; 14 (3): 214–21.
30. Pérez MJ, Quintanilla RA. Therapeutic Actions of the Thiazolidinediones in Alzheimer's Disease. PPAR Res 2015; 2015: 957248.
31. Quinkler M, Diederich S. Difference of in vivo and in vitro antimineralocorticoid potency of progesterone. Endocr Res 2002; 28 (4): 465–70.
32. Rdzak GM, Abdelghany O. Does insulin therapy for type 1 diabetes mellitus protect against Alzheimer's disease? Pharmacotherapy 2014; 34 (12): 1317–23.
33. Rizzo MR, Barbieri M, Boccardi V et al. Dipeptidyl peptidase-4 inhibitors have protective effect on cognitive impairment in aged diabetic patients with mild cognitive impairment. J Gerontol A Biol Sci Med Sci 2014; 69 (9): 1122–31.
34. Shemesh E, Rudich A, Harman-Boehm I et al. Effect of intranasal insulin on cognitive function: a systematic review. J Clin Endocrinol Metab 2012; 97 (2): 366–76.
35. Smith RC, Jin H, Li C et al. Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind study. Schizophr Res 2013; 143 (1): 18–24.
36. Tasci I, Naharci MI, Bozoglu E et al. Cognitive and functional influences of vildagliptin, a DPP-4 inhibitor, added to ongoing metformin therapy in elderly with type 2 diabetes. Endocr Metab Immune Disord Drug Targets 2013; 13 (3): 256–63.
37. Viscogliosi G, Chiriac IM, Andreozzi P et al. The Metabolic Syndrome Predicts Longitudinal Changes in Clock Drawing Test Performance in Older Nondemented Hypertensive Individuals. Am J Geriatr Psychiatry 2016; 24 (5): 359–63.
38. Yi Z, Fan X, Wang J et al. Rosiglitazone and cognitive function in clozapine-treated patients with schizophrenia: a pilot study. Psychiatry Res 2012; 200 (2–3): 79–82.
39. Ying MA, Maruschak N, Mansur R et al. Metformin: repurposing opportunities for cognitive and mood dysfunction. CNS Neurol Disord Drug Targets 2014; 13 (10): 1836–45.
2. Bykov Iu.V., Bekker R.A., Grigor'ev M.E. Perspektivy primeneniia melatonina pri depressivnykh rasstroistvakh (obzor literatury). Consilium Medicum. 2013; 15 (9): 90–5. [in Russian]
3. Bykov Iu.V., Bekker R.A., Reznikov M.K. Depressii i rezistentnost'. M.: INFRA-M, 2013. [in Russian]
4. Mazo G.E., Neznanov N.G. Terapevticheski rezistentnye depressii. SPb.: Beresta, 2012. [in Russian]
5. Atsak P, Guenzel FM, Kantar-Gok D et al. Glucocorticoids mediate stress–induced impairment of retrieval of stimulus-response memory. Psychoneuroendocrinology 2016; 67: 207–15.
6. Baitharu I, Deep SN, Jain V et al. Corticosterone synthesis inhibitor metyrapone ameliorates chronic hypobaric hypoxia induced memory impairment in rat. Behav Brain Res 2012; 228 (1): 53–65.
7. Berent–Spillson A, Briceno E, Pinsky A et al. Distinct cognitive effects of estrogen and progesterone in menopausal women. Psychoneuroendocrinology 2015; 59: 25–36.
8. Bortolato B, Miskowiak KW, Köhler CA et al. Cognitive remission: a novel objective for the treatment of major depression? BMC Med 2016; 14: 9.
9. Castanho TC, Moreira PS, Portugal-Nunes C et al. The role of sex and sex-related hormones in cognition, mood and well-being in older men and women. Biol Psychol 2014; 103: 158–66.
10. Chen B, Jin X, Guo R et al. Metabolic Syndrome and Cognitive Performance Among Chinese ≥50 Years: A Cross-Sectional Study with 3988 Participants. Metab Syndr Relat Disord 2016; 14 (4): 222–7.
11. Crowley SK, O'Buckley TK, Schiller CE et al. Blunted neuroactive steroid and HPA axis responses to stress are associated with reduced sleep quality and negative affect in pregnancy: a pilot study. Psychopharmacology (Berl) 2016; 233 (7): 1299–310.
12. Donoghue K, Rose A, Coulton S et al. Double–blind, 12 month follow-up, placebo-controlled trial of mifepristone on cognition in alcoholics: the MIFCOG trial protocol. BMC Psychiatry 2016; 16: 40.
13. Golier JA, Caramanica K, Michaelides AC et al. A randomized, double-blind, placebo-controlled, crossover trial of mifepristone in Gulf War veterans with chronic multisymptom illness. Psychoneuroendocrinology 2016; 64: 22–30.
14. Grimm A, Mensah-Nyagan AG, Eckert A. Alzheimer, mitochondria and gender. Neurosci Biobehav Rev 2016. pii: S0149–7634(15)30066–X.
15. Guo M, Mi J, Jiang QM et al. Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus. Clin Exp Pharmacol Physiol 2014; 41 (9): 650–6.
16. Hackett G. An update on the role of testosterone replacement therapy in the management of hypogonadism. Ther Adv Urol 2016; 8 (2): 147–60.
17. Hallschmid M, Benedict C, Schultes B et al. Towards the therapeutic use of intranasal neuropeptide administration in metabolic and cognitive disorders. Regul Pept 2008; 149 (1–3): 79–83.
18. Han L, Cai W, Mao L et al. Rosiglitazone Promotes White Matter Integrity and Long-Term Functional Recovery After Focal Cerebral Ischemia. Stroke 2015; 46 (9): 2628–36.
19. Hara Y, Waters EM, McEwen BS et al. Estrogen Effects on Cognitive and Synaptic Health Over the Lifecourse. Physiol Rev 2015; 95 (3): 785–807.
20. Horie NC, Serrao VT, Simon SS et al. Cognitive Effects of Intentional Weight Loss in Elderly Obese Individuals With Mild Cognitive Impairment. J Clin Endocrinol Metab 2016; 101 (3): 1104–12.
21. Howland RH. Mifepristone as a therapeutic agent in psychiatry. J Psychosoc Nurs Ment Health Serv 2013; 51 (6): 11–4.
22. Lehert P, Villaseca P, Hogervorst E et al. Individually modifiable risk factors to ameliorate cognitive aging: a systematic review and meta–analysis. Climacteric 2015; 18 (5): 678–89.
23. Lenze EJ, Hershey T, Newcomer JW et al. Antiglucocorticoid therapy for older adults with anxiety and co–occurring cognitive dysfunction: results from a pilot study with mifepristone. Int J Geriatr Psychiatry 2014; 29 (9): 962–9.
24. Lupien SJ, Wilkinson CW, Brière S et al. Acute modulation of aged human memory by pharmacological manipulation of glucocorticoids. J Clin Endocrinol Metab 2002; 87 (8): 3798–807.
25. Mahmoud R, Wainwright SR, Galea LA. Sex hormones and adult hippocampal neurogenesis: Regulation, implications, and potential mechanisms. Front Neuroendocrinol 2016. pii: S0091–3022(16)30010–3.
26. McIntyre RS, Soczynska JK, Woldeyohannes HO et al. Thiazolidinediones: novel treatments for cognitive deficits in mood disorders? Expert Opin Pharmacother 2007; 8 (11): 1615–28.
27. Mesripour A, Hajhashemi V, Rabbani M. Metyrapone and mifepristone reverse recognition memory loss induced by spontaneous morphine withdrawal in mice. Basic Clin Pharmacol Toxicol 2008; 102 (4): 377–81.
28. Moon JH. Endocrine Risk Factors for Cognitive Impairment. Endocrinol Metab (Seoul) 2016.
29. Ott V, Benedict C, Schultes B et al. Intranasal administration of insulin to the brain impacts cognitive function and peripheral metabolism. Diabetes Obes Metab 2012; 14 (3): 214–21.
30. Pérez MJ, Quintanilla RA. Therapeutic Actions of the Thiazolidinediones in Alzheimer's Disease. PPAR Res 2015; 2015: 957248.
31. Quinkler M, Diederich S. Difference of in vivo and in vitro antimineralocorticoid potency of progesterone. Endocr Res 2002; 28 (4): 465–70.
32. Rdzak GM, Abdelghany O. Does insulin therapy for type 1 diabetes mellitus protect against Alzheimer's disease? Pharmacotherapy 2014; 34 (12): 1317–23.
33. Rizzo MR, Barbieri M, Boccardi V et al. Dipeptidyl peptidase-4 inhibitors have protective effect on cognitive impairment in aged diabetic patients with mild cognitive impairment. J Gerontol A Biol Sci Med Sci 2014; 69 (9): 1122–31.
34. Shemesh E, Rudich A, Harman-Boehm I et al. Effect of intranasal insulin on cognitive function: a systematic review. J Clin Endocrinol Metab 2012; 97 (2): 366–76.
35. Smith RC, Jin H, Li C et al. Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind study. Schizophr Res 2013; 143 (1): 18–24.
36. Tasci I, Naharci MI, Bozoglu E et al. Cognitive and functional influences of vildagliptin, a DPP-4 inhibitor, added to ongoing metformin therapy in elderly with type 2 diabetes. Endocr Metab Immune Disord Drug Targets 2013; 13 (3): 256–63.
37. Viscogliosi G, Chiriac IM, Andreozzi P et al. The Metabolic Syndrome Predicts Longitudinal Changes in Clock Drawing Test Performance in Older Nondemented Hypertensive Individuals. Am J Geriatr Psychiatry 2016; 24 (5): 359–63.
38. Yi Z, Fan X, Wang J et al. Rosiglitazone and cognitive function in clozapine-treated patients with schizophrenia: a pilot study. Psychiatry Res 2012; 200 (2–3): 79–82.
39. Ying MA, Maruschak N, Mansur R et al. Metformin: repurposing opportunities for cognitive and mood dysfunction. CNS Neurol Disord Drug Targets 2014; 13 (10): 1836–45.
2. Быков Ю.В., Беккер Р.А., Григорьев М.Э. Перспективы применения мелатонина при депрессивных расстройствах (обзор литературы). Consilium Medicum. 2013; 15 (9): 90–5. / Bykov Iu.V., Bekker R.A., Grigor'ev M.E. Perspektivy primeneniia melatonina pri depressivnykh rasstroistvakh (obzor literatury). Consilium Medicum. 2013; 15 (9): 90–5. [in Russian]
3. Быков Ю.В., Беккер Р.А., Резников М.К. Депрессии и резистентность. М.: ИНФРА-М, 2013. / Bykov Iu.V., Bekker R.A., Reznikov M.K. Depressii i rezistentnost'. M.: INFRA-M, 2013. [in Russian]
4. Мазо Г.Э., Незнанов Н.Г. Терапевтически резистентные депрессии. СПб.: Береста, 2012. / Mazo G.E., Neznanov N.G. Terapevticheski rezistentnye depressii. SPb.: Beresta, 2012. [in Russian]
5. Atsak P, Guenzel FM, Kantar-Gok D et al. Glucocorticoids mediate stress–induced impairment of retrieval of stimulus-response memory. Psychoneuroendocrinology 2016; 67: 207–15.
6. Baitharu I, Deep SN, Jain V et al. Corticosterone synthesis inhibitor metyrapone ameliorates chronic hypobaric hypoxia induced memory impairment in rat. Behav Brain Res 2012; 228 (1): 53–65.
7. Berent–Spillson A, Briceno E, Pinsky A et al. Distinct cognitive effects of estrogen and progesterone in menopausal women. Psychoneuroendocrinology 2015; 59: 25–36.
8. Bortolato B, Miskowiak KW, Köhler CA et al. Cognitive remission: a novel objective for the treatment of major depression? BMC Med 2016; 14: 9.
9. Castanho TC, Moreira PS, Portugal-Nunes C et al. The role of sex and sex-related hormones in cognition, mood and well-being in older men and women. Biol Psychol 2014; 103: 158–66.
10. Chen B, Jin X, Guo R et al. Metabolic Syndrome and Cognitive Performance Among Chinese ≥50 Years: A Cross-Sectional Study with 3988 Participants. Metab Syndr Relat Disord 2016; 14 (4): 222–7.
11. Crowley SK, O'Buckley TK, Schiller CE et al. Blunted neuroactive steroid and HPA axis responses to stress are associated with reduced sleep quality and negative affect in pregnancy: a pilot study. Psychopharmacology (Berl) 2016; 233 (7): 1299–310.
12. Donoghue K, Rose A, Coulton S et al. Double–blind, 12 month follow-up, placebo-controlled trial of mifepristone on cognition in alcoholics: the MIFCOG trial protocol. BMC Psychiatry 2016; 16: 40.
13. Golier JA, Caramanica K, Michaelides AC et al. A randomized, double-blind, placebo-controlled, crossover trial of mifepristone in Gulf War veterans with chronic multisymptom illness. Psychoneuroendocrinology 2016; 64: 22–30.
14. Grimm A, Mensah-Nyagan AG, Eckert A. Alzheimer, mitochondria and gender. Neurosci Biobehav Rev 2016. pii: S0149–7634(15)30066–X.
15. Guo M, Mi J, Jiang QM et al. Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus. Clin Exp Pharmacol Physiol 2014; 41 (9): 650–6.
16. Hackett G. An update on the role of testosterone replacement therapy in the management of hypogonadism. Ther Adv Urol 2016; 8 (2): 147–60.
17. Hallschmid M, Benedict C, Schultes B et al. Towards the therapeutic use of intranasal neuropeptide administration in metabolic and cognitive disorders. Regul Pept 2008; 149 (1–3): 79–83.
18. Han L, Cai W, Mao L et al. Rosiglitazone Promotes White Matter Integrity and Long-Term Functional Recovery After Focal Cerebral Ischemia. Stroke 2015; 46 (9): 2628–36.
19. Hara Y, Waters EM, McEwen BS et al. Estrogen Effects on Cognitive and Synaptic Health Over the Lifecourse. Physiol Rev 2015; 95 (3): 785–807.
20. Horie NC, Serrao VT, Simon SS et al. Cognitive Effects of Intentional Weight Loss in Elderly Obese Individuals With Mild Cognitive Impairment. J Clin Endocrinol Metab 2016; 101 (3): 1104–12.
21. Howland RH. Mifepristone as a therapeutic agent in psychiatry. J Psychosoc Nurs Ment Health Serv 2013; 51 (6): 11–4.
22. Lehert P, Villaseca P, Hogervorst E et al. Individually modifiable risk factors to ameliorate cognitive aging: a systematic review and meta–analysis. Climacteric 2015; 18 (5): 678–89.
23. Lenze EJ, Hershey T, Newcomer JW et al. Antiglucocorticoid therapy for older adults with anxiety and co–occurring cognitive dysfunction: results from a pilot study with mifepristone. Int J Geriatr Psychiatry 2014; 29 (9): 962–9.
24. Lupien SJ, Wilkinson CW, Brière S et al. Acute modulation of aged human memory by pharmacological manipulation of glucocorticoids. J Clin Endocrinol Metab 2002; 87 (8): 3798–807.
25. Mahmoud R, Wainwright SR, Galea LA. Sex hormones and adult hippocampal neurogenesis: Regulation, implications, and potential mechanisms. Front Neuroendocrinol 2016. pii: S0091–3022(16)30010–3.
26. McIntyre RS, Soczynska JK, Woldeyohannes HO et al. Thiazolidinediones: novel treatments for cognitive deficits in mood disorders? Expert Opin Pharmacother 2007; 8 (11): 1615–28.
27. Mesripour A, Hajhashemi V, Rabbani M. Metyrapone and mifepristone reverse recognition memory loss induced by spontaneous morphine withdrawal in mice. Basic Clin Pharmacol Toxicol 2008; 102 (4): 377–81.
28. Moon JH. Endocrine Risk Factors for Cognitive Impairment. Endocrinol Metab (Seoul) 2016.
29. Ott V, Benedict C, Schultes B et al. Intranasal administration of insulin to the brain impacts cognitive function and peripheral metabolism. Diabetes Obes Metab 2012; 14 (3): 214–21.
30. Pérez MJ, Quintanilla RA. Therapeutic Actions of the Thiazolidinediones in Alzheimer's Disease. PPAR Res 2015; 2015: 957248.
31. Quinkler M, Diederich S. Difference of in vivo and in vitro antimineralocorticoid potency of progesterone. Endocr Res 2002; 28 (4): 465–70.
32. Rdzak GM, Abdelghany O. Does insulin therapy for type 1 diabetes mellitus protect against Alzheimer's disease? Pharmacotherapy 2014; 34 (12): 1317–23.
33. Rizzo MR, Barbieri M, Boccardi V et al. Dipeptidyl peptidase-4 inhibitors have protective effect on cognitive impairment in aged diabetic patients with mild cognitive impairment. J Gerontol A Biol Sci Med Sci 2014; 69 (9): 1122–31.
34. Shemesh E, Rudich A, Harman-Boehm I et al. Effect of intranasal insulin on cognitive function: a systematic review. J Clin Endocrinol Metab 2012; 97 (2): 366–76.
35. Smith RC, Jin H, Li C et al. Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind study. Schizophr Res 2013; 143 (1): 18–24.
36. Tasci I, Naharci MI, Bozoglu E et al. Cognitive and functional influences of vildagliptin, a DPP-4 inhibitor, added to ongoing metformin therapy in elderly with type 2 diabetes. Endocr Metab Immune Disord Drug Targets 2013; 13 (3): 256–63.
37. Viscogliosi G, Chiriac IM, Andreozzi P et al. The Metabolic Syndrome Predicts Longitudinal Changes in Clock Drawing Test Performance in Older Nondemented Hypertensive Individuals. Am J Geriatr Psychiatry 2016; 24 (5): 359–63.
38. Yi Z, Fan X, Wang J et al. Rosiglitazone and cognitive function in clozapine-treated patients with schizophrenia: a pilot study. Psychiatry Res 2012; 200 (2–3): 79–82.
39. Ying MA, Maruschak N, Mansur R et al. Metformin: repurposing opportunities for cognitive and mood dysfunction. CNS Neurol Disord Drug Targets 2014; 13 (10): 1836–45.
________________________________________________
2. Bykov Iu.V., Bekker R.A., Grigor'ev M.E. Perspektivy primeneniia melatonina pri depressivnykh rasstroistvakh (obzor literatury). Consilium Medicum. 2013; 15 (9): 90–5. [in Russian]
3. Bykov Iu.V., Bekker R.A., Reznikov M.K. Depressii i rezistentnost'. M.: INFRA-M, 2013. [in Russian]
4. Mazo G.E., Neznanov N.G. Terapevticheski rezistentnye depressii. SPb.: Beresta, 2012. [in Russian]
5. Atsak P, Guenzel FM, Kantar-Gok D et al. Glucocorticoids mediate stress–induced impairment of retrieval of stimulus-response memory. Psychoneuroendocrinology 2016; 67: 207–15.
6. Baitharu I, Deep SN, Jain V et al. Corticosterone synthesis inhibitor metyrapone ameliorates chronic hypobaric hypoxia induced memory impairment in rat. Behav Brain Res 2012; 228 (1): 53–65.
7. Berent–Spillson A, Briceno E, Pinsky A et al. Distinct cognitive effects of estrogen and progesterone in menopausal women. Psychoneuroendocrinology 2015; 59: 25–36.
8. Bortolato B, Miskowiak KW, Köhler CA et al. Cognitive remission: a novel objective for the treatment of major depression? BMC Med 2016; 14: 9.
9. Castanho TC, Moreira PS, Portugal-Nunes C et al. The role of sex and sex-related hormones in cognition, mood and well-being in older men and women. Biol Psychol 2014; 103: 158–66.
10. Chen B, Jin X, Guo R et al. Metabolic Syndrome and Cognitive Performance Among Chinese ≥50 Years: A Cross-Sectional Study with 3988 Participants. Metab Syndr Relat Disord 2016; 14 (4): 222–7.
11. Crowley SK, O'Buckley TK, Schiller CE et al. Blunted neuroactive steroid and HPA axis responses to stress are associated with reduced sleep quality and negative affect in pregnancy: a pilot study. Psychopharmacology (Berl) 2016; 233 (7): 1299–310.
12. Donoghue K, Rose A, Coulton S et al. Double–blind, 12 month follow-up, placebo-controlled trial of mifepristone on cognition in alcoholics: the MIFCOG trial protocol. BMC Psychiatry 2016; 16: 40.
13. Golier JA, Caramanica K, Michaelides AC et al. A randomized, double-blind, placebo-controlled, crossover trial of mifepristone in Gulf War veterans with chronic multisymptom illness. Psychoneuroendocrinology 2016; 64: 22–30.
14. Grimm A, Mensah-Nyagan AG, Eckert A. Alzheimer, mitochondria and gender. Neurosci Biobehav Rev 2016. pii: S0149–7634(15)30066–X.
15. Guo M, Mi J, Jiang QM et al. Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus. Clin Exp Pharmacol Physiol 2014; 41 (9): 650–6.
16. Hackett G. An update on the role of testosterone replacement therapy in the management of hypogonadism. Ther Adv Urol 2016; 8 (2): 147–60.
17. Hallschmid M, Benedict C, Schultes B et al. Towards the therapeutic use of intranasal neuropeptide administration in metabolic and cognitive disorders. Regul Pept 2008; 149 (1–3): 79–83.
18. Han L, Cai W, Mao L et al. Rosiglitazone Promotes White Matter Integrity and Long-Term Functional Recovery After Focal Cerebral Ischemia. Stroke 2015; 46 (9): 2628–36.
19. Hara Y, Waters EM, McEwen BS et al. Estrogen Effects on Cognitive and Synaptic Health Over the Lifecourse. Physiol Rev 2015; 95 (3): 785–807.
20. Horie NC, Serrao VT, Simon SS et al. Cognitive Effects of Intentional Weight Loss in Elderly Obese Individuals With Mild Cognitive Impairment. J Clin Endocrinol Metab 2016; 101 (3): 1104–12.
21. Howland RH. Mifepristone as a therapeutic agent in psychiatry. J Psychosoc Nurs Ment Health Serv 2013; 51 (6): 11–4.
22. Lehert P, Villaseca P, Hogervorst E et al. Individually modifiable risk factors to ameliorate cognitive aging: a systematic review and meta–analysis. Climacteric 2015; 18 (5): 678–89.
23. Lenze EJ, Hershey T, Newcomer JW et al. Antiglucocorticoid therapy for older adults with anxiety and co–occurring cognitive dysfunction: results from a pilot study with mifepristone. Int J Geriatr Psychiatry 2014; 29 (9): 962–9.
24. Lupien SJ, Wilkinson CW, Brière S et al. Acute modulation of aged human memory by pharmacological manipulation of glucocorticoids. J Clin Endocrinol Metab 2002; 87 (8): 3798–807.
25. Mahmoud R, Wainwright SR, Galea LA. Sex hormones and adult hippocampal neurogenesis: Regulation, implications, and potential mechanisms. Front Neuroendocrinol 2016. pii: S0091–3022(16)30010–3.
26. McIntyre RS, Soczynska JK, Woldeyohannes HO et al. Thiazolidinediones: novel treatments for cognitive deficits in mood disorders? Expert Opin Pharmacother 2007; 8 (11): 1615–28.
27. Mesripour A, Hajhashemi V, Rabbani M. Metyrapone and mifepristone reverse recognition memory loss induced by spontaneous morphine withdrawal in mice. Basic Clin Pharmacol Toxicol 2008; 102 (4): 377–81.
28. Moon JH. Endocrine Risk Factors for Cognitive Impairment. Endocrinol Metab (Seoul) 2016.
29. Ott V, Benedict C, Schultes B et al. Intranasal administration of insulin to the brain impacts cognitive function and peripheral metabolism. Diabetes Obes Metab 2012; 14 (3): 214–21.
30. Pérez MJ, Quintanilla RA. Therapeutic Actions of the Thiazolidinediones in Alzheimer's Disease. PPAR Res 2015; 2015: 957248.
31. Quinkler M, Diederich S. Difference of in vivo and in vitro antimineralocorticoid potency of progesterone. Endocr Res 2002; 28 (4): 465–70.
32. Rdzak GM, Abdelghany O. Does insulin therapy for type 1 diabetes mellitus protect against Alzheimer's disease? Pharmacotherapy 2014; 34 (12): 1317–23.
33. Rizzo MR, Barbieri M, Boccardi V et al. Dipeptidyl peptidase-4 inhibitors have protective effect on cognitive impairment in aged diabetic patients with mild cognitive impairment. J Gerontol A Biol Sci Med Sci 2014; 69 (9): 1122–31.
34. Shemesh E, Rudich A, Harman-Boehm I et al. Effect of intranasal insulin on cognitive function: a systematic review. J Clin Endocrinol Metab 2012; 97 (2): 366–76.
35. Smith RC, Jin H, Li C et al. Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind study. Schizophr Res 2013; 143 (1): 18–24.
36. Tasci I, Naharci MI, Bozoglu E et al. Cognitive and functional influences of vildagliptin, a DPP-4 inhibitor, added to ongoing metformin therapy in elderly with type 2 diabetes. Endocr Metab Immune Disord Drug Targets 2013; 13 (3): 256–63.
37. Viscogliosi G, Chiriac IM, Andreozzi P et al. The Metabolic Syndrome Predicts Longitudinal Changes in Clock Drawing Test Performance in Older Nondemented Hypertensive Individuals. Am J Geriatr Psychiatry 2016; 24 (5): 359–63.
38. Yi Z, Fan X, Wang J et al. Rosiglitazone and cognitive function in clozapine-treated patients with schizophrenia: a pilot study. Psychiatry Res 2012; 200 (2–3): 79–82.
39. Ying MA, Maruschak N, Mansur R et al. Metformin: repurposing opportunities for cognitive and mood dysfunction. CNS Neurol Disord Drug Targets 2014; 13 (10): 1836–45.
Авторы
Р.А.Беккер1, Ю.В.Быков*2
1 Университет им. Давида Бен-Гуриона в Негеве. 8410501, Израиль, Беер-Шева;
2 ГБОУ ВПО Ставропольский государственный медицинский университет Минздрава России. 355017, Россия, Ставрополь, ул. Мира, д. 310
*yubykov@gmail.com
1 David Ben Gurion University in Negev. 8410501, Israel, Be'er Sheva;
2 Stavropol State Medical University of the Ministry of Health of the Russian Federation. 355017, Russian Federation, Stavropol, ul. Mira, d. 310
*yubykov@gmail.com
1 Университет им. Давида Бен-Гуриона в Негеве. 8410501, Израиль, Беер-Шева;
2 ГБОУ ВПО Ставропольский государственный медицинский университет Минздрава России. 355017, Россия, Ставрополь, ул. Мира, д. 310
*yubykov@gmail.com
________________________________________________
1 David Ben Gurion University in Negev. 8410501, Israel, Be'er Sheva;
2 Stavropol State Medical University of the Ministry of Health of the Russian Federation. 355017, Russian Federation, Stavropol, ul. Mira, d. 310
*yubykov@gmail.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.